Technical Analysis for OMER - Omeros Corporation

Grade Last Price % Change Price Change
C 18.06 0.39% 0.07
OMER closed up 0.39 percent on Friday, January 15, 2021, on 1.34 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical OMER trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
Golden Cross Bullish 0.39%
Pocket Pivot Bullish Swing Setup 0.39%
Upper Bollinger Band Walk Strength 0.39%
Older End-of-Day Signals for OMER ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Omeros Corporation Description

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. The company derives product candidates from its proprietary PharmacoSurgery platform that is designed to enhance clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological, and other surgical and medical procedures. The company's product candidates include OMS302, which has completed two Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program for use during arthroscopic procedures comprising partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. Its clinical programs also consist of OMS824, which is in Phase I clinical trial for the treatment of cognitive disorders, including schizophrenia; and OMS405 that is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse. The company's preclinical product development programs comprise OMS721 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; OMS527 for addictions and compulsive disorders, and movement disorders; and OMS616 for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Surgery Inflammation Injury Clinical Research Clinical Trial Disorders Urology Macular Degeneration Ophthalmology Schizophrenia Related Macular Degeneration Hemoglobin Wet Age Related Macular Degeneration Perfusion Movement Disorders Cataract Cognitive Disorders Ischemia Surgical Specialties Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Addiction Intraocular Lens Arthroscopy Hemolytic Uremic Syndrome

Is OMER a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 25.46
52 Week Low 8.5
Average Volume 855,498
200-Day Moving Average 13.47
50-Day Moving Average 13.67
20-Day Moving Average 15.43
10-Day Moving Average 16.17
Average True Range 0.71
ADX 41.25
+DI 40.35
-DI 8.15
Chandelier Exit (Long, 3 ATRs ) 16.37
Chandelier Exit (Short, 3 ATRs ) 16.16
Upper Bollinger Band 17.72
Lower Bollinger Band 13.13
Percent B (%b) 1.07
BandWidth 29.79
MACD Line 1.02
MACD Signal Line 0.77
MACD Histogram 0.2478
Fundamentals Value
Market Cap 1.11 Billion
Num Shares 61.7 Million
EPS -2.08
Price-to-Earnings (P/E) Ratio -8.68
Price-to-Sales 7.09
Price-to-Book 0.00
PEG Ratio -0.17
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.14
Resistance 3 (R3) 19.17 18.83 18.96
Resistance 2 (R2) 18.83 18.56 18.82 18.90
Resistance 1 (R1) 18.45 18.39 18.28 18.42 18.84
Pivot Point 18.11 18.11 18.03 18.10 18.11
Support 1 (S1) 17.73 17.84 17.56 17.70 17.28
Support 2 (S2) 17.39 17.67 17.38 17.22
Support 3 (S3) 17.01 17.39 17.16
Support 4 (S4) 16.98